New asthma drug AK139 enters phase II trial: hope for better breathing?
NCT ID NCT07436221
First seen Mar 29, 2026 · Last updated May 15, 2026 · Updated 7 times
Summary
This study tests a new drug called AK139 in 160 adults with moderate to severe asthma. The goal is to see if it improves lung function and reduces airway inflammation safely. Participants will receive either AK139 or a placebo, and researchers will monitor side effects and immune responses.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ASTHMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shanghai General Hospital
Shanghai, China
-
The First Affiliated Hospital of Guangzhou Medical University
Guangzhou, China
Conditions
Explore the condition pages connected to this study.